"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
| Descriptor ID |
D002945
|
| MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
| Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 8 | 11 |
| 1996 | 3 | 8 | 11 |
| 1997 | 3 | 8 | 11 |
| 1998 | 3 | 7 | 10 |
| 1999 | 1 | 6 | 7 |
| 2000 | 2 | 5 | 7 |
| 2001 | 1 | 8 | 9 |
| 2002 | 2 | 4 | 6 |
| 2003 | 2 | 4 | 6 |
| 2004 | 4 | 7 | 11 |
| 2005 | 5 | 11 | 16 |
| 2006 | 2 | 7 | 9 |
| 2007 | 1 | 6 | 7 |
| 2008 | 2 | 9 | 11 |
| 2009 | 2 | 7 | 9 |
| 2010 | 1 | 8 | 9 |
| 2011 | 1 | 12 | 13 |
| 2012 | 4 | 6 | 10 |
| 2013 | 2 | 7 | 9 |
| 2014 | 0 | 7 | 7 |
| 2015 | 2 | 4 | 6 |
| 2016 | 6 | 8 | 14 |
| 2017 | 3 | 4 | 7 |
| 2018 | 5 | 6 | 11 |
| 2019 | 5 | 5 | 10 |
| 2020 | 7 | 9 | 16 |
| 2021 | 5 | 6 | 11 |
| 2022 | 0 | 8 | 8 |
| 2023 | 1 | 8 | 9 |
| 2024 | 3 | 5 | 8 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
3D genome organization shapes DNA damage susceptibility to platinum-based drugs. Nucleic Acids Res. 2025 May 22; 53(10).
-
DNA damage causes ATM-dependent heterochromatin loss leading to nuclear softening, blebbing, and rupture. Mol Biol Cell. 2025 Mar 01; 36(3):br6.
-
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 Nov; 10(11):1565-1570.
-
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 09 28; 404(10459):1240-1252.
-
Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy. JAMA Oncol. 2024 Jul 01; 10(7):912-922.
-
Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. Mol Cancer. 2024 Jun 10; 23(1):121.
-
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024 Aug; 19(8):1228-1241.
-
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. J Clin Oncol. 2024 Apr 20; 42(12):1403-1414.
-
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
-
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023 Dec 18; 32(1):36.